Novel Tissue Oximeter Technology

New technology called optical diffusion imaging and spectroscopy (ODIS) enables noninvasive, direct, real-time estimation of local tissue oxygen saturation (StO2) on a very cost-effective basis. A new tissue oximeter incorporating the technology has been cleared by the U.S. Food and Drug Administration (FDA).

The new oximeter is called ODISsey and was developed by ViOptix (Fremont, CA, USA), a developer and manufacturer of tissue oxygen measuring devices. The new technology will be used in diagnostic and monitoring equipment for a wide variety of clinical applications.

"This is a key achievement for us and for noninvasive tissue oxygen assessment in general,” noted Mohamed Elmandjra, president and CEO of ViOptix. "We are committed to bringing innovative products with high clinical value to the healthcare market, and FDA clearance is definitely a major milestone toward that goal.”




Related Links:
ViOptix